社区

Accordingly, the recent release underscored a lower-than-expected efficacy, indicating Moderna's "RSV vaccine might be less effective than initially thought." As a result, I believe the market is likely pricing in execution risks in its pipeline, affecting the competitiveness of its RSV vaccine. Moderna investors should be keenly aware of the criticality of its RSV vaccine as a crucial growth vector as the company looks forward following the success of its COVID franchise. Notwithstanding the caution, Moderna is still expected to receive FDA approval for its RSV vaccine, helping to alleviate some concerns. At a recent January conference, Moderna management highlighted that it "anticipates regulatory approvals for its RSV vaccine beginning in the first half of 2024." Therefore, investors must carefully assess management's commentary about the data release at its upcoming earnings conference. Given the recent updates, a